This site uses features not supported by Internet Explorer.

Cancer Risks of the Weight Loss Drug Belviq - An Emerging Litigation
< Back to Webinars
Cancer Risks of the Weight Loss Drug Belviq - An Emerging Litigation

The weight loss drug Belviq (lorcaserin) was initially approved by the FDA in 2012 as an add-on treatment for obesity and in those experiencing obesity-related health issues. The medication worked by controlling the appetite by activating brain receptors for serotonin to trigger feelings of fullness. During a review of clinical safety trials, the FDA found an increased occurrence of cancers in subjects who took Belviq compared to the placebo group. There may also be risk of other injuries.

It appears the manufacturers may have deceived the FDA, knew or should have known about the link between Belviq and cancer for years but withheld the information from consumers, regulators and the medical community.

What You Can Expect to Learn

  • The drug’s regulatory history
  • An overview of the science
  • Potential for injuries and other cancer
  • Potential Daubert and other science-related issues affecting cases

Webinar

We're sorry you missed the webinar. You can still see a recording by filling out the form below.

Gain Access

Presented By

  • Aimee Wagstaff - Andrus Wagstaff
  • David Wool - Andrus Wagstaff